Nutriband (NASDAQ:NTRB) Releases Earnings Results

Nutriband (NASDAQ:NTRB) announced its quarterly earnings data on Thursday. The company reported ($0.10) EPS for the quarter, Zacks reports. Nutriband had a negative net margin of 403.98% and a negative return on equity of 118.33%.

Nutriband Price Performance

Shares of NASDAQ:NTRB opened at $3.52 on Friday. The company’s fifty day moving average is $3.75 and its two-hundred day moving average is $4.18. The company has a quick ratio of 6.21, a current ratio of 6.36 and a debt-to-equity ratio of 0.01. Nutriband has a 12-month low of $3.21 and a 12-month high of $11.68. The company has a market cap of $42.80 million, a P/E ratio of -1.35 and a beta of 1.90.

Institutional Trading of Nutriband

A hedge fund recently raised its stake in Nutriband stock. Vanguard Group Inc. raised its position in shares of Nutriband Inc. (NASDAQ:NTRB) by 1.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 202,738 shares of the company’s stock after purchasing an additional 3,111 shares during the quarter. Vanguard Group Inc. owned 1.68% of Nutriband worth $1,429,000 at the end of the most recent quarter. Institutional investors own 19.70% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Nutriband from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, June 3rd. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce”.

About Nutriband

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility.